Investment Thesis
Cardiff Oncology is a pre-revenue clinical-stage biotech company with severe cash burn (-$37.9M operating cash flow) and minimal revenue ($593K), indicating the company is not yet commercializing products effectively. With only 17.5 months of cash runway at current burn rates and no clear path to profitability, the company faces significant financial distress risk despite having zero debt.
Strengths
- Strong liquidity position with 3.67x current ratio providing near-term operational flexibility
- Zero long-term debt eliminates financial leverage risk and provides balance sheet flexibility
- Positive equity cushion of $45.4M provides some buffer against losses
Risks
- Severe cash burn of $37.9M annually with only $17.5M cash on hand represents critical runway risk
- Revenue of $593K is negligible and declining 13.2% YoY, indicating failed commercialization or clinical translation
- Operating losses of $49.0M and negative net margin of -7732% demonstrate unsustainable unit economics with no viable business model
Key Metrics to Watch
- Quarterly cash burn rate and cash runway remaining
- Revenue growth and drug pipeline advancement towards commercialization
- Clinical trial success rates and regulatory milestones for product candidates
Financial Metrics
Revenue
593.0K
Net Income
-45.9M
EPS (Diluted)
$-0.69
Free Cash Flow
-38.0M
Total Assets
61.9M
Cash
17.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-8,256.3%
Net Margin
-7,732.0%
ROE
-101.0%
ROA
-74.1%
FCF Margin
-6,402.5%
Balance Sheet & Liquidity
Current Ratio
3.67x
Quick Ratio
3.67x
Debt/Equity
0.00x
Debt/Assets
26.7%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-22T23:24:11.774680 |
Data as of: 2025-12-31 |
Powered by Claude AI